Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.

Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, Wolff M, Klimov A, Levandowski R, Lambert L.

Vaccine. 2002 Jan 15;20(7-8):1099-105.

PMID:
11803070
2.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
3.

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.

Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium.

Arch Intern Med. 2008 Dec 8;168(22):2405-14. doi: 10.1001/archinternmed.2008.513.

PMID:
19064822
4.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
5.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

PMID:
16586358
6.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
7.

Dose sparing with intradermal injection of influenza vaccine.

Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.

N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3.

8.

Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.

Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.

Vaccine. 2009 Jun 2;27(27):3561-7. doi: 10.1016/j.vaccine.2009.03.062. Epub 2009 Apr 10.

PMID:
19464535
9.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.

N Engl J Med. 2009 Dec 17;361(25):2405-13. doi: 10.1056/NEJMoa0907413. Epub 2009 Sep 10.

10.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
11.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.

J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916.

PMID:
18694338
12.

Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.

Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC.

J Med Virol. 2009 May;81(5):908-14. doi: 10.1002/jmv.21456.

PMID:
19319953
13.

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.

Vaccine. 2009 Jan 14;27(3):454-9. doi: 10.1016/j.vaccine.2008.10.077. Epub 2008 Nov 18.

PMID:
19022318
14.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
15.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
16.

Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.

Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ.

Vaccine. 2010 Aug 16;28(36):5857-63. doi: 10.1016/j.vaccine.2010.06.060. Epub 2010 Jun 30.

PMID:
20600483
17.

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.

Vaccine. 2009 Dec 9;27(52):7304-12. doi: 10.1016/j.vaccine.2009.10.033. Epub 2009 Oct 20.

PMID:
19849996
18.
19.

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M.

J Infect Dis. 2008 Sep 1;198(5):650-8. doi: 10.1086/590434.

PMID:
18652550
20.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.

Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27.

PMID:
19716456

Supplemental Content

Support Center